A Selective Alkylating Agent for CTG Repeats in Myotonic Dystrophy Type 1

Area of Science:

• Molecular Biology
• Genetics
• Drug Discovery

Background:

• Genome editing technologies like CRISPR-Cas9 offer therapeutic potential but face delivery challenges.
• Targeting DNA directly for disease intervention has been limited by off-target effects.

Purpose of the Study:

• To develop a selective DNA-modifying small molecule for myotonic dystrophy type 1 (DM1).
• To investigate the therapeutic potential of targeting disease-specific DNA structures in DM1.

Main Methods:

• A novel small molecule ligand was designed to alkylate T-T mismatch-containing hairpins in expanded CTG repeats (d(CTG)exp).
• The effect of ligand alkylation on transcription of d(CAG·CTG)exp and toxic r(CUG)exp transcript levels was assessed.
• DM1 model cells were used to evaluate the ligand's bioactivity, including effects on disease foci and pre-mRNA splicing.

Main Results:

• The small molecule selectively alkylated disease-specific DNA structures in DM1.
• Alkylation inhibited transcription and reduced toxic RNA levels, alleviating DM1 pathological features in model cells.
• The ligand demonstrated potential to alter repeat length dynamics in DM1 patient cells.

Conclusions:

• A selective DNA-modifying small molecule offers a promising therapeutic strategy for DM1 by targeting aberrant DNA structures.
• This approach may be applicable to other repeat expansion diseases, including Huntington's disease and amyotrophic lateral sclerosis.